
MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for …

MSD has lifted the curtain on strong Phase 3 results in the development of its investigational antiviral drug letermovir, showing …

The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …

MSD, known as Merck in North America, has announced that it has been forced to cancel a Phase 2/3 trial …

Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …

The good news keeps coming for MSD, known as Merck in North America, and Keytruda, with a further label expansion …

MSD, known as Merck in North America, has taken a pre-emptive step in the drug pricing debate by releasing its …

Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be …

The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …

MSD, known as Merck in North America, and Eli Lilly have announced the expansion of their existing immuno-oncology collaboration. The …

MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority …

With a new year comes a fresh start, and so it was the case with Sanofi and MSD’s joint vaccine …

The National Institute of Health and Care Excellence (NICE) has announced its recommendation of MSD’s immunotherapy drug Keytruda (pembrolizumab) for …

MSD has released new data which reinforces the efficacy of its anti-PD-1 therapy pembrolizumab in patients with advanced urothelial (bladder) …